WAVE Life Sciences (NASDAQ:WVE) Raised to Strong-Buy at Truist Financial

WAVE Life Sciences (NASDAQ:WVE) was upgraded by Truist Financial to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Several other equities analysts have also weighed in on WVE. Cantor Fitzgerald increased their price target on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Royal Bank Of Canada raised shares of WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $9.00 to $27.00 in a research report on Monday, December 8th. Canaccord Genuity Group boosted their target price on shares of WAVE Life Sciences from $43.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. UBS Group set a $32.00 target price on shares of WAVE Life Sciences in a research report on Tuesday, December 16th. Finally, Leerink Partners restated an “outperform” rating on shares of WAVE Life Sciences in a research note on Monday, December 8th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.31.

WAVE Life Sciences Trading Up 5.8%

WVE stock opened at $12.30 on Wednesday. The stock has a market cap of $2.32 billion, a P/E ratio of -10.08 and a beta of -1.77. The stock’s fifty day simple moving average is $13.24 and its two-hundred day simple moving average is $11.24. WAVE Life Sciences has a 1-year low of $5.28 and a 1-year high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last announced its earnings results on Thursday, February 26th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.02). The business had revenue of $17.25 million for the quarter, compared to analysts’ expectations of $15.68 million. WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. As a group, analysts forecast that WAVE Life Sciences will post -1.14 earnings per share for the current fiscal year.

Insider Transactions at WAVE Life Sciences

In other WAVE Life Sciences news, CEO Paul Bolno sold 10,480 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $140,956.00. Following the completion of the transaction, the chief executive officer owned 275,520 shares in the company, valued at $3,705,744. This trade represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Chris Francis sold 33,194 shares of WAVE Life Sciences stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $15.05, for a total transaction of $499,569.70. Following the completion of the transaction, the insider owned 61,867 shares of the company’s stock, valued at $931,098.35. The trade was a 34.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 61,748 shares of company stock valued at $907,809. 23.98% of the stock is currently owned by insiders.

Institutional Trading of WAVE Life Sciences

A number of institutional investors have recently modified their holdings of WVE. CWM LLC lifted its stake in WAVE Life Sciences by 6,729.0% in the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock worth $36,000 after purchasing an additional 2,086 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of WAVE Life Sciences by 645.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,243 shares of the company’s stock valued at $38,000 after purchasing an additional 1,942 shares in the last quarter. Bessemer Group Inc. grew its position in shares of WAVE Life Sciences by 1,156.3% during the 3rd quarter. Bessemer Group Inc. now owns 9,925 shares of the company’s stock valued at $72,000 after purchasing an additional 9,135 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of WAVE Life Sciences by 1,441.6% in the third quarter. Russell Investments Group Ltd. now owns 9,928 shares of the company’s stock worth $73,000 after purchasing an additional 9,284 shares during the period. Finally, Ameritas Investment Partners Inc. increased its holdings in shares of WAVE Life Sciences by 18.7% in the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock worth $74,000 after purchasing an additional 1,802 shares during the period. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Mizuho raised its price target on WVE from $22 to $27 and kept an “outperform” rating, representing a large upside vs. the stock’s current level; analyst upgrades like this can drive buying interest and raise investor confidence. Benzinga: Mizuho raises WVE target
• Positive Sentiment: Coverage summarizing Q4 drivers highlights what boosted WAVE in Q4 (revenue strength and institutional attention referenced by fund letters such as Loomis Sayles). Positive quarter commentary and signs of reaccelerating small-cap earnings help justify higher targets and attract momentum investors. Here’s What Boosted Wave Life Sciences Ltd. (WVE) in Q4
• Neutral Sentiment: Analyst roundups and media pieces (e.g., Globe and Mail) are discussing WVE alongside other healthcare names — these summaries increase visibility but do not by themselves change fundamentals. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Market-commentary pieces and stock reviews (AmericanBankingNews) have mentioned WVE alongside peers; useful for context but not a clear directional catalyst. Reviewing BioAtla & WAVE Life Sciences
• Neutral Sentiment: Reports flagged unusually high options activity and a reported increase in short-interest for March, but the published short-interest figures appear inconsistent (0 shares / NaN changes), suggesting a reporting/data error — watch for clarified filings before treating this as a bearish signal. WAVE Life Sciences Target of Unusually High Options Trading

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.